Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Trial Profile

An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Angle-closure glaucoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eyenovia
  • Most Recent Events

    • 28 Nov 2018 Results presented in an Eyenovia media release.
    • 28 Nov 2018 According to an Eyenovia media release, results from this study were published in the November 2018 issue of the peer-review journal Clinical Ophthalmology.
    • 13 Nov 2018 According to an Eyenovia media release, data from the study have been accepted for publication by the peer-reviewed journal Clinical Ophthalmology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top